
Please try another search
For the three months ended 31 March 2022, Clarus Therapeutics Holdings Inc revenues increased 72% to $4M. Net loss applicable to common stockholders decreased 23% to $14.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest expense decrease of 58% to $2M (expense), Change in fair value of warrant liabilit increase from $0K to $642K (income).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 4.01 | 4.56 | 4.29 | 5.11 |
Gross Profit | 3.35 | 3.27 | 3.78 | 4.19 |
Operating Income | -13.55 | -7.27 | -5.93 | -24.03 |
Net Income | -14.87 | -4.3 | -2.77 | -33.55 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 36.52 | 51.71 | 45.32 | 28.33 |
Total Liabilities | 66.88 | 67.63 | 70.85 | 185.74 |
Total Equity | -30.36 | -15.92 | -25.52 | -157.42 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -17.27 | -43.79 | -34.45 | -21.93 |
Cash From Investing Activities | -0.01 | -0.03 | -0.02 | -0.02 |
Cash From Financing Activities | 0 | 62.99 | 49.19 | 25 |
Net Change in Cash | -17.28 | 19.18 | 14.72 | 3.04 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review